G1 THERAPEUTICS (NASDAQ:GTHX)‘s stock had its “buy” rating reaffirmed by analysts at Cowen and Company in a report released on Wednesday.

The analysts wrote, “G1 Therapeutics reported a Q3 net loss of $16MM and September 30 cash of.””

Separately, Zacks Investment Research lowered shares of G1 THERAPEUTICS from a “hold” rating to a “sell” rating in a research note on Wednesday, October 11th. One equities research analyst has rated the stock with a sell rating and four have assigned a buy rating to the company. The stock currently has an average rating of “Buy” and an average target price of $29.75.

Shares of G1 THERAPEUTICS (GTHX) traded down $0.08 on Wednesday, hitting $20.51. 13,262 shares of the stock were exchanged, compared to its average volume of 83,613. G1 THERAPEUTICS has a 1 year low of $12.04 and a 1 year high of $28.67.

G1 THERAPEUTICS (NASDAQ:GTHX) last released its quarterly earnings data on Wednesday, August 9th. The company reported ($1.09) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($0.61) by ($0.48). sell-side analysts predict that G1 THERAPEUTICS will post -2.7 EPS for the current fiscal year.

ILLEGAL ACTIVITY WARNING: “G1 THERAPEUTICS (GTHX) Stock Rating Reaffirmed by Cowen and Company” was originally published by Watch List News and is the property of of Watch List News. If you are accessing this report on another domain, it was illegally stolen and republished in violation of international copyright legislation. The correct version of this report can be read at https://www.watchlistnews.com/g1-therapeutics-gthx-stock-rating-reaffirmed-by-cowen-and-company/1693666.html.

Hedge funds have recently added to or reduced their stakes in the business. American International Group Inc. purchased a new stake in shares of G1 THERAPEUTICS during the third quarter valued at about $130,000. Alps Advisors Inc. purchased a new stake in shares of G1 THERAPEUTICS during the second quarter valued at about $444,000. Bank of New York Mellon Corp purchased a new stake in shares of G1 THERAPEUTICS during the third quarter valued at about $568,000. Victory Capital Management Inc. purchased a new stake in shares of G1 THERAPEUTICS during the second quarter valued at about $889,000. Finally, Goldman Sachs Group Inc. purchased a new stake in shares of G1 THERAPEUTICS during the second quarter valued at about $1,144,000. 35.18% of the stock is owned by institutional investors and hedge funds.

About G1 THERAPEUTICS

G1 Therapeutics, Inc is a United States-based clinical-stage biopharmaceutical company. The Company is engaged in developing small-molecule therapies for the treatment of cancer. Its two clinical-stage candidates are trilaciclib (G1T28) and G1T38, which are potent, selective inhibitors of the validated kinase targets CDK4/6.

Receive News & Ratings for G1 THERAPEUTICS Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for G1 THERAPEUTICS and related companies with Analyst Ratings Network's FREE daily email newsletter.